AxxessBio partners with Gennisium in the area of Neonatology
October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®. Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon. Apnea in preterm infants is common in babies born at less